American Society of Clinical Oncology (ASCO) Virtual Scientific Program ...

American Society of Clinical Oncology (ASCO) Virtual Scientific Program 2020 Friday, May 29 ? Sunday, May 31



Cancer Center Members indicated in BOLD

Plenary Session

(LBA2) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Breast Cancer--Local/Regional/Adjuvant ? Local-Regional Therapy Sunday, May 31, 2020, 1:00 PM ET Authors: Seema Ahsan Khan, Fengmin Zhao, Lawrence J. Solin, Lori J. Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B. Julian, Barbara A. Pockaj, Christine A Lee, Wajeeha Razaq, Joseph A. Sparano, Gildy V Babiera, Irene Ang Dy, Sarika Jain, Paula Silverman, Carla Fisher, Amye Juliet Tevaarwerk, Lynne I. Wagner, George W. Sledge; Northwestern Memorial Hospital, Chicago, IL; Dana?Farber Cancer Institute, Malden, MA; Albert Einstein Medical Center, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; McGill University, Jewish General Hospital Segal Cancer Centre, Montr?al, QC, Canada; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; NRG Oncology, and The Allegheny Health Network Cancer Institute, Pittsburgh, PA; Mayo Clinic, Phoenix, AZ; Swedish Medical Center, Seattle, WA; NSABP Foundation and Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK; Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY; University of Texas MD Anderson Cancer Center, Houston, TX; St. Luke's-Roosevelt Hospital, Effingham, IL; Northwestern University Division of Hematology/Oncology, Chicago, IL; University Hospitals Case Medical Center, Cleveland, OH; Indiana University School of Medicine, Indianapolis, IN; University of Wisconsin Carbone Cancer Center, Madison, WI; Wake Forest University Health Sciences, Winston Salem, NC; Stanford University School of Medicine, Stanford, CA

Clinical Science Symposium

MET Mutations: The Meat of the Matter (9510) Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced nonsmall cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14). Authors: D. Ross Camidge, Filip Janku, Alejandro Martinez-Bueno, Daniel V.T. Catenacci, Jeeyun Lee, SeHoon Lee, Afshin Dowlati, Kristoffer Staal Rohrberg, Alejandro Navarro, Yong Wha Moon, Mark M. Awad, Rebecca Suk Heist, Thomas Tuxen Poulsen, Arielle Yablonovitch, Lindsay Fosler, Helle Rudbaek, Frank Nygaard, Debra L. Wood, Rita P. Dalal, Enriqueta Felip; Medical Oncology Department, University of Colorado, Aurora, CO; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX; Instituto Oncol?gico Dr Rosell, Hospital Universitario Quir?n Dexeus, Barcelona, Spain; University of Chicago Medical Center and Biological Sciences, Chicago, IL; Samsung Medical Center, Seoul, South Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospital of

Cancer Center members indicated in BOLD

Copenhagen Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; CHA Bundang Medical Center, CHA University, Bundang, South Korea; Massachusetts General Hospital, Cambridge, MA; Massachusetts General Hospital, Boston, MA; Symphogen A/S, Ballerup, Denmark; Bioinformatics, Guardant Health, Redwood City, CA; Guardant Health, Redwood City, CA; Nadler Pharma Associates, LLC, Randolph, NJ; Formerly Eli Lilly and Company, Bridgewater, NJ; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Oral Abstract Sessions

(1002) TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). Oral Abstract Session: Breast Cancer--Metastatic Authors: Nadine M. Tung, Mark E. Robson, Steffen Ventz, Cesar Augusto Santa-Maria, Paul Kelly Marcom, Rita Nanda, Payal D Shah, Tarah Jean Ballinger, Eddy Shih-Hsin Yang, Michelle E. Melisko, Adam Brufsky, Shaveta Vinayak, Michelle Demeo, Colby Jenkins, Susan M. Domchek, Gerburg M. Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Judy Ellen Garber, Translational Breast Cancer Research Consortium; Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Brookline, MA; Northwestern University Feinberg School of Medicine, Chicago, IL; Duke University Medical Center, Durham, NC; The University of Chicago, Chicago, IL; University of Pennsylvania, Philadelphia, PA; Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medcl Ctr, Boston, MA; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA

(6003) A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. Oral Abstract Session: Gynecologic Cancer Authors: Joyce F. Liu, Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, Noelle Gillette Cloven, Carolyn Muller, David Bender, Richard G. Moore, David Paul Michelin, Steven E. Waggoner, Melissa Ann Geller, Keiichi Fujiwara, Stacy D. D'Andre, Michael Carney, Angeles Alvarez Secord, Katherine M. Moxley, Michael A. Bookman; Dana-Farber Cancer Institute, Boston, MA; Roswell Park Cancer Institute, Buffalo, NY; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD; University of Washington School of Medicine, Seattle, WA; Memorial Sloan Kettering Cancer Center, New York, NY; Texas Oncology, Ft. Worth, TX; University of New Mexico, Albuquerque, NM; University of Iowa, Iowa City, IA; University of Rochester Medical Center, Rochester, NY; Cancer Research Consortium of West Michigan, Grand Rapids, MI; Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, OH; University of Minnesota, Minneapolis, MN; Saitama Medical University International Medical Center, Hidaka, Japan; Sutter Medical Group, Sacramento, CA; University of Hawaii, Honolulu, HI; Duke Cancer Institute, Duke University Medical Center, Durham, NC; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Kaiser Permanente Northern California, San Francisco, CA

(9000) Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. Oral Abstract Session: Lung Cancer--Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Authors: Ticiana Leal, Yating Wang, Afshin Dowlati, DeQuincy Andrew Lewis, Yuanbin Chen, Amit

ASCO Annual Meeting 2020

[2]

Cancer Center members indicated in BOLD

Ramesh Mohindra, Mohammad Razaq, Harish G. Ahuja, Jijun Liu, David M. King, Christopher Joseph Sumey, Suresh S. Ramalingam; University of Wisconsin Carbone Cancer Center, Madison, WI; ECOG-ACRIN Biostatistics Center, Boston, MA; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH; Randolph Cancer Ctr, Asheboro, NC; Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI; Ramesh K Mohindra MD PC, Franklin, MI; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Aspirus Reg Cancer Ctr, Wausau, WI; Illinois Cancer Care, Peoria, IL; Minnesota Onc, St Paul, MN; Univ of Colorado, Aurora, CO; Winship Cancer Institute, Emory University Hospital, Atlanta, GA

Poster Discussion Sessions

(5019) Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. Poster Discussion Session: Genitourinary Cancer--Kidney and Bladder Authors: Hristos Z. Kaimakliotis, Nabil Adra, William Kevin Kelly, Edouard John Trabulsi, Richard C. Lauer, Joel Picus, Zachary L Smith, Radhika Walling, Timothy A. Masterson, Adam C Calaway, Michael O. Koch, Elizabeth Sonderman, Pingfu Fu, Gordon Goolamier, Cheryl Eitman, Lee Evan Ponsky, Christopher J. Hoimes; Indiana University Simon Cancer Center, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Washington University in St. Louis School of Medicine, St. Louis, MO; Washington University School of Medicine, St Louis, MO; Community Cancer Center, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; Seidman Cancer Center at University Hospitals Cleveland Medical Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Duke Cancer Institute, Durham, NC

(8520) A phase II, single-arm study of denosumab in multiple myeloma patients with renal insufficiency. Poster Discussion Session: Hematologic Malignancies--Plasma Cell Dyscrasia Authors: Elizabeth O'Donnell, Andrew Jenho Yee, Omar Nadeem, Brea Lipe, Jacob Laubach, Ehsan Malek, Andrew Branagan, Robb S. Friedman, Paul G. Richardson, Ajay K. Nooka, Noopur S. Raje; Massachusetts General Hospital Cancer Center, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; University of Rochester, Rochester, NY; Adult Hematologic Malignancies and Stem Cell Transplant Section, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH; Beth Israel Deaconess Cancer Ctr Needham, Newton, MA; Dana Farber Cancer Institute, Boston, MA; Winship Cancer Institute of Emory University, Atlanta, GA

Poster Sessions

(528) Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer. Breast Cancer--Local/Regional/Adjuvant ? Adjuvant Therapy Authors: Cynthia Owusu, Seunghee P Margevicius, Heidi D. Klepin, Charles L. Vogel, Asrar Alahmadi, Sowjanya Vuyyala, Adam Brufsky; Case Western Reserve University School of Medicine, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Comprehensive Cancer Center, Wake Forest Baptist Health, Winston Salem, NC; Sylvester At Deerfield Beach, Deerfield Beach, FL; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; University of Pittsburgh Medical Center, Division of Hematology Oncology, Pittsburgh, PA

(572) Impact of axillary lymph node dissection (ALND) on survival in patients with ypN1 breast cancer that receive regional nodal irradiation (RNI): A national cancer database (NCDB) analysis.

ASCO Annual Meeting 2020

[3]

Cancer Center members indicated in BOLD

Breast Cancer--Local/Regional/Adjuvant ? Local-Regional Therapy Authors: Michael Kharouta, Nicholas Damico, Eleanor Elizabeth Harris, Janice A. Lyons; University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH

(3583) Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors. Developmental Therapeutics--Molecularly Targeted Agents and Tumor Biology - New Targets and New Technologies (non-IO) Authors: John Sarantopoulos, Devalingam Mahalingam, Neelesh Sharma, Renuka V. Iyer, Wen Wee Ma, Manmeet Singh Ahluwalia, Saramarie Johnson, Andrei Purmal, Polina Shpigotskaya, Ann Hards, Andrey Leonov, Katerina Gurova, Andrei Gudkov, Kristina Zakurdaeva, Langdon L. Miller, Afshin Dowlati; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX; Northwestern University, Chicago, IL; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Mayo Clinic, Rochester, MN; Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Neurological Institute, Taussig Cancer Institute and Cleveland Clinic, Cleveland, OH; Incuron, Inc, Buffalo, NY; Incuron, LLC, Moscow, Russian Federation

(3634) A randomized, controlled trial of structured palliative care versus standard supportive care for patients enrolled on phase I clinical trials. Developmental Therapeutics--Molecularly Targeted Agents and Tumor Biology ? Other Authors: Michelle Elizabeth Treasure, Barbara J. Daly, PingFu Fu, Shufen Cao, Neal J. Meropol, Afshin Dowlati; Cleveland Clinic Foundation, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Flatiron Health, New York, NY and Case Comprehensive Cancer Center, Cleveland, OH; Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH

(4062) Initial correlative studies from a trial of cetuximab and pembrolizumab in metastatic colorectal cancer (mCRC). Gastrointestinal Cancer--Colorectal and Anal ? Biologic Correlates Authors: Patrick M Boland, Jason Muhitch, Scott I Abrams, Orla Maguire, Hans Minderman, David Lawrence Bajor, Joel N. Saltzman, Katy Wang, Alan Hutson, Sarbajit Mukherjee, Renuka V. Iyer, Pawel Kalinski, Christos Fountzilas; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Roswell Park Cancer Institute, Buffalo, NY; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Roswell Park Comprehensive Cancer Center, Buffalo, NY

(4623) Survival outcomes of patients with resectable pancreatic cancer treated with upfront surgery versus neoadjuvant chemotherapy: A retrospective tertiary care center experience. Gastrointestinal Cancer--Gastroesophageal, Pancreatic, and Hepatobiliary ? Pancreatic Cancer Authors: Fang Liu, Matthew Mirsky, Sulin Wu, Pingfu Fu, Shufen Cao, John Shanahan, Ravi Kumar Kyasaram, Prantesh Jain, Jeffrey Hardacre, John Brian Ammori, Jordan Michael Winter, David Lawrence Bajor; University Hospital, Cleveland, OH; University Hospitals of Cleveland, Cleveland, OH; Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH; Department of Biostats and Epidemiology, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; University Hospitals-Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Memorial Sloan Kettering Cancer Center, New York, NY; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

ASCO Annual Meeting 2020

[4]

Cancer Center members indicated in BOLD

(4643) A pilot study to determine the feasibility of a customized low glycemic load diet in patients with stage I-III colorectal cancer. Gastrointestinal Cancer--Gastroesophageal, Pancreatic, and Hepatobiliary ? Other GI Cancer Authors: Michelle Elizabeth Treasure, Alicia Thomas, Stephen Ganocy, Augustine Hong, Smitha S. Krishnamurthi, David Lawrence Bajor, Nathan A. Berger, Neal J. Meropol; Cleveland Clinic Foundation, Cleveland, OH; Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Cleveland Clinic Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Western Reserve Univ, Cleveland, OH; Flatiron Health, New York, NY and Case Comprehensive Cancer Center, Cleveland, OH

(5047) Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. Genitourinary Cancer--Kidney and Bladder - Bladder Cancer Authors: Christopher J. Hoimes, Nabil Adra, Mark T. Fleming, Hristos Z. Kaimakliotis, Joel Picus, Zachary L Smith, Radhika Walling, Edouard John Trabulsi, Jean H. Hoffman-Censits, Michael O. Koch, Clint Cary, Robert Abouassaly, Cheryl Eitman, Pingfu Fu, Gordon Goolamier, Adam C Calaway, Lee Evan Ponsky, William Kevin Kelly; Duke Cancer Institute, Durham, NC; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Virginia Oncology Associates, US Oncology Research, Norfolk, VA; Indiana University Simon Cancer Center, Indianapolis, IN; Washington University in St. Louis School of Medicine, St. Louis, MO; Washington University School of Medicine, St Louis, MO; Community Cancer Center, Indianapolis, IN; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Glickman Urology and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH; Department of Population and Quantitative Health Science, Case Western Reserve University, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Seidman Cancer Center at University Hospitals Cleveland Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH; Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

(6093) Genomic and transcriptomic profiles of gynecologic neuroendocrine carcinoma are distinct from pulmonary neuroendocrine small cell carcinoma. Gynecologic Cancer ? Other Cancer Authors: Haider Mahdi, Amy Joehlin-Price, Afshin Dowlati, Ata Abbas; Cleveland Clinic, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH

(7027) Effect of shorter time to treatment on survival in rural patients with breast cancer. Health Services Research and Quality Improvement ? Disparities/Access to Care Authors: Suneel Deepak Kamath, Wei Wei, Katherine Tullio, Gregory S. Cooper, Alok A. Khorana; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; Cleveland Clinic- Taussig Cancer Institute, Cleveland, OH

(7526) Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion indepe Hematologic Malignancies--Leukemia, Myelodysplastic Syndromes, and Allotransplant ? Acute Leukemia Authors: Amer Methqal Zeidan, Michael Schuster, Magalie Joris, Jurgen Krauter, Johan Maertens,

ASCO Annual Meeting 2020

[5]

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download